


Nicolau, MC¹; Neto, PN¹; Santos, PTS; Simão, TA²; Pinto, LFR^{1,2}; Lima, SCS¹

¹Programa de Carcinogênese Molecular– CPQ – Instituto Nacional de Câncer, Brazil;

²Departamento de Bioquímica – IBRAG – Universidade do Estado do Rio de Janeiro, Brazil.

INTRODUCTION


- Esophageal squamous cell carcinoma (ESCC) is one of the main histological types of esophageal cancer worldwide and in Brazil^{1,2}. Although its high incidence and mortality rates, the mechanisms that lead to ESCC development are still poorly understood³.
- Alterations of DNA methylation are a common event in ESCC and may precede the first genetic alterations, however what leads to this deregulation is still unknown⁴. The specific pattern of DNA methylation depends on the balance between methylation and demethylation processes⁵.
- More recently, APOBEC proteins (cytidine deaminases), related to the generation of genetic variability, have also been implicated in active DNA demethylation⁶ as well as TET proteins, which are involved in the hydroxylation of 5-methylcytosine⁷. Besides, an APOBEC-mediated mutational signature in ESCC suggests that APOBEC-catalyzed deamination provides a source of mutations in ESCC⁸.



OBJECTIVE

- To evaluate the expression profile of APOBECs and TETs in ESCC and the functional consequences of their possible deregulation


HYPOTHESIS




METHODOLOGY

- The mRNA expression of APOBECs and TETs was determined by RT-qPCR in tumor and matched surrounding non-tumor tissue from 30 patients with a confirmed diagnosis of ESCC;
- A receiver operating characteristic (ROC) curve was plotted for the use of gene expression as a marker to distinguish normal-appearing surrounding mucosa and tumor tissue;
- TP53* mutations were evaluated by NGS in ESCC and correlated with APOBECs expression.


RESULTS



Evaluation of APOBECs gene expression in ESCC patients. Evaluation by RT-qPCR of the mRNA expression of *APOBEC3A1* (A), *APOBEC3B* (B), *APOBEC3D* (C), *APOBEC3FA* (D) and *APOBEC3G* (E) in non-tumor surrounding mucosa and tumor tissue from ESCC patients. * $p < 0.0001$, Wilcoxon signed rank test.



Receiver operating characteristic (ROC) curve for the discrimination of normal-appearing surrounding mucosa and tumor tissue of ESCC patients, according to APOBEC3B expression. For an *APOBEC3B* expression cut-off of 0.004386, the area under the curve (AUC) was 0.9911, with a sensitivity of 93.33% and a specificity of 100%, $p < 0.0001$.



Association of *TP53* mutation type with *APOBEC3FA* expression. The overexpression of *APOBEC3FA* was associated with C>T *TP53* mutations. * $p = 0.0287$, Kruskal Wallis test and Dunn's post-test.

The most common *TP53* mutations were AT>GC (41%) followed by CG>TA (28%).

CONCLUSION


- The deregulation of the APOBEC family of genes is a common feature in ESCC and may be associated with the occurrence of *TP53* mutations.

REFERENCES

- Parkin DM, et al (2005). CA Cancer J Clin. 55(2):74-108;
- INCA. Estimativa 2016/2017: Incidência de Câncer no Brasil. Instituto Nacional de Câncer José Alencar Gomes da Silva, Coordenação de Prevenção e Vigilância. Rio de Janeiro: INCA, 2016 [Internet]. Available from: <http://www.inca.gov.br/wcm/dncc/2015/index.asp>, accessed on 2016 Jan 7.
- Napier KJ, Scheerer M, Misra S. (2014). World J Gastrointest Oncol. 6(5):112-20;
- Lima SC, et al (2011). Epigenetics. 6(10):1217-27
- Ciesielski P, et al (2015). Postepy Hig Med Dosw (Online). 69:1371-83.
- Knisbacher BA, Gerber D, Levanon EY. (2016). Trends Genet. 32(1):16-28.
- Tahiliani M, et al (2009). Science. 324(5929):930-5.
- Zhang L, et al (2015). Am J Hum Genet. 96(4):597-611.
- Meng H et al (2014). Int J Mol Sci. 15(12):22604-25.

Funding source: Ministério da Saúde, FAPERJ.

Projeto Gráfico: Serviço de Edição e Informação Técnico-Científica / INCA



Evaluation of TETs gene expression in ESCC patients. Evaluation by RT-qPCR of the mRNA expression of *TET1* (A) and *TET2* (B) in non-tumor surrounding mucosa and tumor tissue from ESCC patients. * $p < 0.05$, Wilcoxon signed rank test.